AMENDMENT TO PROPERTY LEASE AGREEMENT by the Company “SOGEBAIL” in favor of the Company “INNATE PHARMA”Property Lease Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances)
Maître Roselyne BOTELLA , a notary in the “SCP THIBIERGE ET ASSOCIES, Notaries, members of a private professional partnership holding a Notarial Office,” with headquarters in PARIS (eighth district), 9 rue d’Astorg,
JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENTLicence Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201Development and License Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
THIS SECOND AMENDMENT TO THE CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201 (this “Second Amendment”) is made and entered into as of July 26, 2019 (the “Amendment Effective Date”), by and between MedImmune Limited, a company organized under the laws of England and Wales (“MedImmune”) and Innate Pharma S.A, a company organized under the laws of France (“Innate”). MedImmune and Innate are each referred to in this Amendment as a “Party” and collectively, as the “Parties”.
LICENSE AGREEMENT -between- MEDIMMUNE LIMITED -and- INNATE PHARMA S.A. LICENSE AGREEMENTLicense Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
WHEREAS, MedImmune is, directly or indirectly, a wholly owned subsidiary of AstraZeneca PLC (AstraZeneca PLC and its Affiliates being “AstraZeneca”). MedImmune and its Affiliates have experience in the research, development, manufacturing and commercialization of pharmaceutical products worldwide, including treatments for cancer both using small molecules and large molecules.
ContractCollaboration and Option Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
